Home/Pipeline/SnapCure Antibody

SnapCure Antibody

Oncology (Undisclosed)

DiscoveryInferred Active

Key Facts

Indication

Oncology (Undisclosed)

Phase

Discovery

Status

Inferred Active

Company

Impact Biomedical

About Impact Biomedical

Impact Biomedical Inc. is a U.S.-based public biotech company focused on translating its proprietary platform technologies into novel therapeutics for oncology and virology. The company's strategy centers on advancing its Equivir platform for viral oncolysis and its SnapCure platform for antibody discovery through internal R&D and strategic collaborations. While still pre-revenue and in early clinical/preclinical stages, its platform-based approach aims to generate multiple high-value product candidates, though it faces significant execution and funding risks typical of micro-cap biotechs.

View full company profile

Therapeutic Areas

Oncology Virology

Other Oncology (Undisclosed) Drugs

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
NEX-20	Nanexa	Preclinical	Active
NEX-18	Nanexa	Preclinical	Active
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active